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Abstract 
Background: A high prevalence of cannabis use disorder has been reported in subjects suffering from schizophre-
nia, fuelling intense debate about whether schizophrenia with pre-onset cannabis use disorder may be a distinct 
entity with specific features or whether cannabis use disorder can precipitate schizophrenia in genetically vulnerable 
subjects.
Methods: We retrospectively assessed schizophrenia subjects with and without pre-onset cannabis use disorder on 
the basis of their clinical features, assessed categorically and dimensionally with the operational criteria checklist for 
psychotic illnesses (OCCPI). We also investigated whether the two groups could be differentiated on the basis of a 
history of psychiatric disorders in first-degree relatives. A principal component factor analysis of the OCCPI items was 
used to identify specific symptom dimensions. The relationships between symptom dimensions and cannabis status 
were analysed by point-biserial correlation analysis to control for sex and age at time of the assessment and illness 
duration.
Results: One hundred and seventy-one subjects with a diagnosis of schizophrenia were included. Among them, 
forty-one patients (18.2 % of the sample) had a cannabis use disorder before or at the time of the onset of schizophre-
nia. We found similar results in symptoms patterns or family history between patients with and without pre-onset 
cannabis use disorder.
Conclusions: Our results clearly argue against cannabis-associated schizophrenia being a relevant distinct clinical 
entity of schizophrenia with specific features.
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Background
A high prevalence of cannabis use has repeatedly been 
reported in psychotic patients [1]. Previous systematic 
reviews have reported a wide range (13–45 %) in the rates 
of cannabis use disorders (CUD) in schizophrenia users 
[2, 3], with a median lifetime rate estimated at 27.1  % 
[4]. Apart from the fact that acute intoxication can lead 
to ‘psychotic-like’ experiences that do not persist beyond 
the period of intoxication [5], various possibilities have 
been discussed for the association between cannabis 
and schizophrenia which include: (a) cannabis use is a 
component cause of schizophrenia; (b) the hypothesis of 
“self-medication” for symptoms of psychiatric diseases 
such as the negative symptoms of schizophrenia, anxiety, 
depression or dysphoria and (c) common socio-demo-
graphic factors and shared genetic factors.
Several studies have shown that the use of cannabis 
leads to physiological and cognitive deficits of a similar 
nature to those seen in schizophrenia [6]. In particular, 
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there is an increasing body of evidence demonstrating 
that cannabis users (without schizophrenia) show defi-
cits in tasks of sustained attention, working memory and 
other executive functions [7], as well as abnormalities in 
automatic processing of auditory stimuli: P50 suppres-
sion [8], prepulse inhibition (PPI) [9] and the mismatch 
negativity (MMN) [10] of the event-related potential 
(ERP). This suggests that dysfunctions in the endocan-
nabinoid system could be involved in the development of 
similar deficits associated with cannabis use and schizo-
phrenia, and further proposes that the neurobiology 
underpinning the development of electrophysiological/
cognitive deficits in cannabis users may overlap with the 
neurobiological underpinnings of schizophrenia.
Other data suggest that the link between cannabis 
use and schizophrenia might be causal, even if a direct 
cause–effect relationship between the two disorders has 
not been clearly established. Systematic reviews regard-
ing the association between cannabis and psychosis have 
suggested that cannabis can increase the lifetime risk of 
psychosis by a factor of two or three [11–13] and meta-
analytic approaches found that the risk of psychosis was 
approximately 40 % higher in cannabis users than in non-
users [14]. In the causal hypothesis, cannabis use may be 
directly involved in the pathophysiological processes that 
lead to a distinct form of schizophrenia-spectrum disor-
der that would have never happened otherwise. This is 
different from the hypothesis in which cannabis use may 
act as a precipitating factor in genetically vulnerable sub-
jects. In this case, cannabis use would be expected only 
to precipitate the onset of schizophrenia. The causal 
hypothesis has been extensively discussed, and the diag-
nosis of “cannabis-induced schizophrenia” also known as 
“cannabis-associated schizophrenia” remains controver-
sial [15]. Indeed, if “cannabis-associated schizophrenia” 
was a specific clinical entity, one would have expected to 
find specific clinical features including symptomatic pro-
files, course and prognosis.
Several studies have explored these hypotheses by 
comparing clinical characteristics between subjects who 
reported having used cannabis before the onset of schiz-
ophrenia and those who had not used cannabis before 
the onset of schizophrenia. Most studies have focused on 
samples of patients with a first-episode psychosis, making 
it possible to rule out the use of cannabis for self-medica-
tion [16] or to alleviate the side effects of antipsychotic 
medication. Several of these first-episode studies [17, 18] 
reported differences in clinical characteristics for individ-
uals with cannabis use, including an earlier age at onset 
(for a meta-analysis, please refer to [19]). However, most 
of these studies found no such relationship [1, 20, 21], 
and failed to identify a specific clinical profile in cannabis 
users before the onset of the illness (for review, see [22]). 
These discrepancies might be due to uncertainties related 
to the diagnosis, including misclassifications of subjects 
during their first-psychotic episode. Similarly, studies 
exploring the symptom profiles of subjects with estab-
lished schizophrenia with and without cannabis use have 
yielded conflicting results. Some have suggested that can-
nabis users had a different clinical profile, with more pos-
itive and less negative symptoms [23, 24], whereas others 
have found no difference between cannabis users or for-
mer users and non-users [25–27].
There is a relative lack of studies comparing specifically 
the clinical profiles of subjects suffering from schizophre-
nia with and without cannabis use before the onset of 
the illness. Such studies have again provided conflicting 
results concerning possible associations with various fac-
tors, such as premorbid social functioning, rates of posi-
tive and negative symptoms and overall prognosis [23, 
26, 28–31]. Thus, it remains largely unknown whether 
cannabis-associated schizophrenia could be considered 
as a valid distinct clinical entity with a different course, 
including symptom expression and burden.
These discrepancies between studies may result from 
different factors. Firstly, the consequences of cannabis 
use on symptom profiles may be different in patients 
with CUD when compared to other cannabis users (e.g. 
through higher dose [32] or specific vulnerability). Sec-
ondly, discrepancies may result partly from differences in 
inclusion criteria or in the assessment procedures used. 
For example, in most studies, positive and negative symp-
toms are measured with clinical scales, such as the scale 
for the assessment of positive symptoms (SAPS), the 
Scale for the assessment of negative symptoms (SANS), 
the brief psychiatric rating scale (PBRS) and the positive 
and negative syndrome scale (PANSS), which are suit-
able for the assessment of symptoms in a cross-sectional 
approach, whereas the use of an instrument profiling 
symptoms over a lifetime perspective may possibly be 
more valid and reliable for assessments of the effects of 
cannabis use on schizophrenia. Of note, several studies 
analysing the factors underlying schizophrenia and other 
psychotic disorders have used the operational criteria 
checklist for psychotic illnesses (OCCPI) [33–36] and 
have shown that OCCPI factor analysis is a highly reliable 
method for lifetime dimensional phenotype description 
in schizophrenia.
To explore whether schizophrenia with pre-onset CUD 
could be a valid diagnostic entity with a specific symp-
tomatic expression, we investigated the impact of pre-ill-
ness CUD on lifetime specific symptom patterns derived 
from the OCCPI in a relatively large sample of well-
characterized subjects suffering from schizophrenia. We 
expected differences in symptom dimension profiles and 
clinical characteristics between schizophrenia subjects 
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with and without pre-onset CUD. We also investigated 
whether it was possible to differentiate schizophrenia 
subjects with pre-onset CUD and those without on the 
basis of their history of psychiatric disorders in first-
degree relatives. We hypothesized that subjects with-
out pre-onset CUD would have a higher familial genetic 
liability to schizophrenia (higher rates of positive family 
history of schizophrenia) than schizophrenia subjects 
with pre-onset CUD. As far as we know, this is the first 
study to use OCCPI factor analysis to compare symptom 
profiles between schizophrenia subjects with and without 
pre-onset CUD in a lifetime perspective.
Methods
Subjects
Consecutively admitted subjects suffering from schiz-
ophrenia were recruited from a university-affiliated 
hospital (AP-HP, Pôle de Psychiatrie et d’Addictologie, 
Créteil, France). All probands included met DSM-IV-
R criteria for schizophrenia and were interviewed by an 
experienced psychiatrist with the French version of the 
Diagnostic Interview for Genetic Studies (DIGS) [37] to 
confirm the diagnosis. Familial psychiatric morbidity was 
investigated with the Family Interview for Genetic Stud-
ies (FIGS) [38]. A complete family history for first-degree 
relatives was obtained from each subject and at least one 
first-degree relative. All subjects were euthymic at the 
time of the study, as evaluated with the Montgomery and 
Asberg Depression Rating Scale (MADRS) and the Beck-
Rafaelson Mania Assessment Scale (MAS).
The study was reviewed and approved by the Research 
Ethics Board. All participants were provided with a com-
plete description of the study and gave written informed 
consent.
Clinical assessments
Socio-demographic characteristics, age at onset, num-
ber of hospital admissions and personal history of sui-
cide attempts were recorded on the basis of both medical 
notes and data extracted from the DIGS. Patients were 
also assessed for lifetime cannabis and other sub-
stance use, and were asked to state precisely when use 
had begun, its duration and the mode of consumption. 
Patients were assigned to the “pre-onset CUD” group 
if they met lifetime DSM-IV-R criteria for cannabis use 
disorders (cannabis abuse or dependence) before or at 
the time of schizophrenia onset. Otherwise, they were 
assigned to the “no pre-onset” CUD group. Patients with 
other substance use disorders were excluded with an 
exception for tobacco smoking. Age at onset of schizo-
phrenia was defined as the age at which the patient first 
met DSM-IV-R criteria for schizophrenia, according to 
medical case notes and interviews.
Assessment of symptom dimensions and OCCPI ratings
The Operational Criteria Checklist for Psychotic Illness 
(OCCPI) [39] consists of 90 items assessing clinical char-
acteristics and symptoms used in a wide range of opera-
tional diagnostic systems. We chose to use the OCCPI 
because (1) the presence of symptoms is recorded cat-
egorically; (2) a wide range of psychotic symptoms are 
recorded; (3) it is designed to assess symptoms that have 
occurred at some point in the subject’s life (lifetime per-
spective); (4) it records affective symptom data and (5) 
it can make use of data from different interviews. The 
OCCPI was completed, for the lifetime occurrence of 
symptoms by two raters using the DIGS and the infor-
mation from interviews recorded in case notes. The 
inter-rater reliability (Kappa) of factorial scores was 
assessed for 30 test cases and was found to be very good 
[Kappa = 0.84, 95 % CI (0.59, 0.75)].
Data analyses
Principal component analysis (PCA)
The aim of a principal component analysis is to reduce 
the number of variables used to describe a sample, by 
choosing linearly uncorrelated variables called princi-
pal components. All items defining a single symptom 
(n = 48) were chosen and coded dichotomously. We per-
formed a principal component analysis on 28 symptoms 
of the OCCPI (20 symptoms were excluded due to a lack 
of variance or >10 % missing data). We extracted the ini-
tial factors and then performed an orthogonal rotation 
by the VARIMAX method. The number of meaningful 
factors was determined by the scree plot. For each of the 
symptom dimensions identified, OCCPI items with a 
loading greater than 0.4 were used to construct a quanti-
tative scale. Subjects were scored by calculating the pro-
portion of items present for each symptom dimension. 
Each subject was thus given a symptom pattern score for 
each of the scales.
The scree plot indicated that there were four substan-
tive factors accounting for 46  % of the variance. The 
following symptom dimensions were identified: Fac-
tor 1 (affective: 11 items): loss of energy/tiredness, loss 
of pleasure, poor concentration, slowed activity, ini-
tial insomnia, poor appetite, dysphoria, excessive self-
reproach, increased self-esteem, irritable mood and 
suicidal ideation; Factor 2 (reality distortion: 9 items): 
primary delusional perception, other primary delusion, 
delusions of passivity, bizarre delusions, auditory hallu-
cinations (1), Clérambault-Kandinsky complex (2), non-
affective hallucination of any type, delusions of influence 
and grandiose delusions; Factor 3 (disorganized/negative: 
5 items): inappropriate affect, restricted/blunted affect, 
negative formal thought disorder, bizarre behaviour and 
positive formal thought disorder (3) and Factor 4 (motor: 
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3 items): delusions of guilt, agitated activity and catato-
nia. The affective factor accounted for 20.3 % of the total 
variance, reality distortion accounted for 12.4 %, the dis-
organized/negative factor for 7.0 % and the motor factor 
for 6.0 % (Table 1).
Statistical methods
Data were analysed with PASW Statistics version 18.0 
(IBM, Chicago, Ill, USA). We compared schizophrenia 
subjects with and without pre-onset CUD in terms of 
demographic and clinical variables, including sex, family 
history of psychiatric disorders, age at onset of schizo-
phrenia, illness duration, personal or familial history of 
suicide attempts. The differences between groups were 
assessed with the Student t test or Man-Whitney test for 
continuous variables and Pearson’s Chi-squared or Fish-
er’s exact tests for discrete variables, and a p value <0.004 
adjusted for Bonferroni correction was considered sta-
tistically significant. The relationships between symptom 
dimensions and CUD status were analysed by Spear-
man point-biserial correlations to control for the poten-
tial confounding influences of sex, age at the time of the 
assessment and illness duration.
We also carried out logistic regressions to assess the 
effects of categorical and dimensional variables on the 
likelihood that patients had CUD before the onset of 
schizophrenia. We included in the first model only cat-
egorical variables that were found significantly differ-
ent between the pre-onset CUD and “no pre-onset” 
CUD schizophrenia groups (sex, age at assessment and 
Table 1 Factor loadings for OCCPI items following varimax rotation
Highest factor loading for each item in italics type
Factor loading <0.3 are not shown
a Auditory hallucinations: third-person auditory hallucinations and/or running commentary voices and/or other (non affective) auditory hallucinations
b Clérambault–Kandinsky complex: thought insertion and/or thought withdrawal and/or thought broadcast and/or thought echo
c Positive formal thought disorder: positive formal thought disorder and/or speech difficult to understand and/or incoherent
Principal component Affective Reality distortion Disorganised/negative Motor
Loss of energy/tiredness 0.84







Increased self esteem 0.48
Irritable mood 0.47
Suicidal ideation 0.4
Primary delusional perception 0.76
Other primary delusions 0.66




Non-affective hallucination of any type 0.54
Delusions of influence 0.53
Grandiose delusions 0.39
Inappropriate affect 0.67
Restricted/ blunted affect 0.66
Negative formal thought disorder 0.56
Bizarre behaviour 0.48
Positive formal thought disorderc 0.44
Delusions of guilt 0.56
Agitated activity 0.31
Catatonia −0.62
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duration of illness). The second model included both cat-
egorical and dimensional variables. Duration of illness 
was removed from the models because of a risk of sin-
gularity between “age at assessment” and “duration of ill-
ness”. All assumptions of logistic regression models were 
met, including independence of cases, exclusion of mul-
ticollinearity and linear relationship between continuous 
independent variables and the logit transformation of the 
dependent variable. We estimated the variance explained 
by predicting variables using Nagelkerke’s R2.
Results
Sample characteristics
The initial sample consisted of 207 subjects diagnosed 
with schizophrenia. Thirty-six subjects (17.4  %) had a 
DSM-IV-R lifetime diagnosis for a substance use disorder 
other than cannabis and were thus excluded.
The final sample was composed of 171 subjects and was 
predominantly males (67.1  %). The mean age at assess-
ment was 34.0 years (SD 11.7). The mean age at onset was 
23.7 years (SD 7.9), and the mean duration of illness was 
11.5 years (SD 11.1).
Pre‑onset CUD vs. “no pre‑onset” CUD: categorical 
variables
Demographic and clinical characteristics are detailed in 
(Table  1). Thirty-five subjects (20.5  % of the total sam-
ple) met DSM-IV-R criteria for CUD (cannabis abuse 
or dependence) without comorbid other substance use 
disorder. Among the 35 subjects with CUD, 31 subjects 
began using cannabis before or at the time of schizo-
phrenia onset and were thus assigned to the pre-onset 
CUD group. There were significantly fewer women in the 
pre-onset CUD group and these subjects were younger 
than those in the “no pre-onset” CUD group.
The mean age at onset of schizophrenia did not dif-
fer significantly between the two subgroups following 
Bonferroni correction. The pre-onset CUD group had a 
shorter duration of illness than the “no pre-onset” CUD 
group. There was no difference in the number of hospital 
admissions per year between the two groups. There were 
also no significant differences between the two groups in 
terms of the proportions of people with a positive fam-
ily history of schizophrenia, mood disorders or suicide 
attempts (Table 2).
Pre‑onset CUD vs. “no pre‑onset” CUD: symptom 
dimension features
No significant difference between the groups was found 
for any of the symptom dimensions (affective (r = 0.05; 
p =  0.46), reality distortion (r =  0.08; p =  0.34), disor-
ganized/negative (r =  0.04; p =  0.62), motor (r =  0.04; 
p = 0.63)) after controlling for sex and age at the time of 
the assessment) (Fig. 1).
Logistic regressions
The first logistic regression model was statistically signifi-
cant [X2(2) =  28.47, p  <  0.001]. The proportion of vari-
ance explained was 25.1 %. On the two variables included 
in this first model, male and younger subjects had higher 
likelihood of belonging to the pre-onset CUD group with 
respective odds of 15.76, IC95  =  (2.06–120.43) and of 
0.94, IC95 = (0.89–0.98).
The second logistic regression model included both 
demographical variables and the four factor scores. 
The results were not substantially changed. The model 
Table 2 Comparisons of  the demographic and  clinical characteristics of  subjects belonging to  the schizophrenia (SZ) 
with and without pre-onset cannabis use disorder (pre-onset CUD)
Significant p values after Bonferroni correction (threshold p < 0.004) are presented in italics
SD standard deviation, n number
Total sample SZ with no pre‑onset CUD SZ with pre‑onset CUD p
Number of subjects 171 140 31 –
Male [n (%)] 114 (67.1%) 84 (60.4%) 30 (96.8%) <0.001
Mean age at assessment [years (SD)] 34.0 (11.7) 35.4 (12.1) 27.6 (6.8) 0.001
Mean age at onset [years (SD)] 23.7 (7.9) 24.4 (8.5) 20.9 (3.4) 0.027
Mean age at cannabis use onset [years (SD)] – – 18.3 (3.7) –
Mean duration of the illness [years (SD)] 11.5 (11.1) 12.6 (11.7) 6.7 (6.7) 0.007
Mean number of hospital admissions/illness duration 0.6 (0.7) 0.6 (0.8) 0.6 (0.4) 0.82
Personal history of suicide attempts [n (%)] 75 (45.5%) 65 (47.8%) 10 (34.5%) 0.19
Family history of schizophrenia [n (%)] 16 (10.2%) 12 (9.4%) 4 (13.3%) 0.53
Family history of mood disorders [n (%)] 66 (44.0%) 56 (46.3%) 10 (34.5%) 0.25
Family history of suicide attempts [n (%)] 26 (17.6%) 23 (19.3%) 3 (10.3%) 0.25
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remained significant [X2(6)  =  30.32, p  <  0.001] and 
explained 26.6  % of the variance group difference. 
Male and younger patients were more likely to be clas-
sified to the schizophrenia with pre-onset CUD group, 
while no factor score was significantly associated with 
group membership when controlling for demographic 
variables (Tables 3,  4).
Discussion
We carried out a detailed comparison of schizophrenia 
subjects with and without pre-onset CUD, using cate-
gorical and lifetime dimensional approaches. Contrary to 
our expectations, we did not find any clear symptom pat-
tern differentiating the two groups of subjects.
Categorical approach
The lifetime prevalence rate of CUD in our sample is 
within the range of lifetime prevalence rates (13–45  %) 
previously reported in schizophrenia [1, 3] and is very 
similar to the rate of 27  % reported by Koskinen et  al. 
[4]. Men and women account for similar proportions of 
the schizophrenia population, but most controlled clini-
cal trials have found men to be over-represented among 
substance users with schizophrenia [24, 40–44]. The pro-
portion of men was higher in our pre-onset CUD group 
than in the “no pre-onset” CUD group, which included 
only four patients with CUD beginning after the onset of 
schizophrenia and mostly patients without lifetime CUD. 
However, this predominance of men among cannabis 
users is not specific to psychotic disorders. In a recent 
Table 3 Logistic regression predicting likelihood of  schizophrenia with  pre-onset cannabis use disorder for  the first 
model including categorical variables
a Male gender is coded “1” and female gender “0”, patients with pre-onset CUD were coded “1” and those without “0”
B SE df p Odds ratio 95% Confidence interval 
for odds ratio
Lower Upper
Sexa 2.76 1.04 1 0.008 15.76 2.06 120.43
Age at assessment −0.06 0.02 1 0.007 0.94 0.89 0.98
Table 4 Logistic regression predicting likelihood of schizophrenia with pre-onset cannabis use disorder for the second 
model including categorical variables and factor scores
a Male gender is coded “1” and female gender “0”, patients with pre-onset CUD were coded “1” and those without “0”




 Sexa 2.79 1.05 1 0.008 16.29 2.09 126.75
 Age at assessment −0.07 0.03 1 0.008 0.93 0.89 0.98
Factor scores
 Affective 0.06 0.08 1 0.47 1.06 0.91 1.14
 Reality distortion 0.09 0.09 1 0.31 1.10 0.92 1.32
 Disorganised/negative 0.02 0.17 1 0.91 1.02 0.72 1.43
 Motor 0.07 0.24 1 0.77 1.07 0.66 1.73
Fig. 1 Comparisons of symptom dimensions (factor scores) between 
schizophrenia with and without pre-onset cannabis use disorder
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survey, it was estimated that rates of cannabis use dur-
ing the past month were about 10 % for male subjects and 
6 % for female subjects [45].
Several studies [44, 46–48] but not all [49–51] 
reported that substance users have an earlier onset of 
the disease. More recently, a meta-analysis has con-
firmed the link between cannabis use and an earlier 
age at onset of schizophrenia [19]. However, the stud-
ies included in this meta-analysis did not take into 
account whether the substance was used prior to the 
onset of psychosis, or later in the course of established 
schizophrenia. In our sample, the age at onset was not 
different between the two groups of patients, thus not 
favouring the hypothesis of the illness being triggered 
by substance use as it has been suggested in people pre-
disposed to psychosis [12]. Subjects with schizophrenia 
and substance use have been reported to have a history 
of more lifetime suicide attempts [52, 53]. In our sam-
ple, the frequency of suicide attempts was not differ-
ent between subjects with and without pre-onset CUD. 
Thus, our results with others [54] do not favour the 
hypothesis that CUD prior the onset of schizophrenia 
acts as a mediator of suicidality.
In accordance with some [24, 42] but not all previous 
studies [55], we found no difference between the groups 
in terms of the percentage of patients with a positive fam-
ily history of schizophrenia using a careful semi-stand-
ardized familial assessment. This result also adds weight 
to the criticisms of the validity of the diagnosis of “can-
nabis-associated schizophrenia” being a distinct clini-
cal entity. Indeed, if hereditary predisposition had been 
found to differ between subjects with pre-onset CUD and 
“no pre-onset” CUD, this might have provided some indi-
rect support for the validity of this diagnosis.
Dimensional approach
We found no difference in lifetime symptom dimensions 
between subjects with schizophrenia according to their 
personal history of CUD before the onset of schizophre-
nia. The magnitudes of the various symptom dimen-
sions were very similar in the two groups. Most studies 
comparing cannabis users and non-users at the time 
of a first-psychotic episode or in a context of chronic 
schizophrenia did not evidence a relationship between 
cannabis use and symptoms [4, 20, 24, 42, 56–58]. A 
few studies have reported evidence of association with 
greater positive symptoms [59–61] or lesser negative 
symptoms [23, 62, 63]. Methodological differences may 
explain such discrepancies. Indeed, using a reliable life-
time dimensional approach, our findings clearly argue 
against “cannabis-associated schizophrenia” being a dis-
tinct clinical entity.
Strengths and limitations of the study
The major advantage of this study is the use of a factorial 
analytical method to identify lifetime symptom dimen-
sions related to a specific psychopathological domain. 
Our sample consisted of well-characterized subjects, 
and the information about family history was also care-
fully collected with a semi-standardized instrument. We 
also chose to include subjects with established schizo-
phrenia rather than first-episode subjects to reduce the 
risk of uncertainties related to the diagnosis. Finally, we 
excluded subjects with other substance abuse or depend-
ence to avoid biases related to other substance such as 
alcohol or opiates.
Several methodological limitations should be con-
sidered. Firstly, we defined our group based on their 
history of abuse or dependence to cannabis before the 
onset of schizophrenia and not their consumption. The 
rationale for our decision was driven by retrospective 
design. Indeed, retrospective self-report of canna-
bis use (e.g. by reporting daily dose) might be highly 
impacted by recall and declaration biases. To improve 
data accuracy, we used a structured assessment tool 
that has a very good reliability to assess CUD [64]. 
The second limitation is that we cannot rule out an 
effect of medication use on the clinical profiles of sub-
jects. Thirdly, our dimensional approach did rely on a 
principal component analysis that did not distinguish 
separate negative and disorganized dimensions in our 
sample. We therefore cannot exclude the possibility 
of an association between pre-onset CUD and one of 
these dimensions. Finally, in our PCA, the extracted 
components explained 46  % of the variance in the 
symptom data being recorded. This may seem low, but 
this value is in the range seen in all the studies using 
the same instrument and the same statistical methodol-
ogy (mean: 52.2 % range 39–71 %).
Conclusions
Finding differences between schizophrenia subjects 
with and without pre-onset CUD in terms of symptom 
patterns would be of interest. Indeed, this would sug-
gest that the pathological mechanisms underlying the 
symptoms of schizophrenia when associated with a 
pre-onset CUD can be induced by a direct pharmaco-
logical effect of cannabis use. This would have provided 
some validity to a putative “cannabis-associated schizo-
phrenia” diagnosis. Taken together, our results clearly 
do not support the hypothesis of “cannabis-associated 
schizophrenia” being a distinct nosographic entity. 
Firstly, we found no specific symptom profiles in the 
pre-onset CUD group. Secondly, we found that gender 
and a younger age were associated with the pre-onset 
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CUD group. However, these factors have been previ-
ously identified in samples of cannabis users without 
psychosis [59, 60] and are non-specific factors. Thirdly, 
we did not find a higher percentage of positive family 
history of schizophrenia in the “no pre-onset” CUD 
group, thus not supporting the hypothesis that genetic 
factors contributes more significantly in this group. 
Future prospective birth cohort and population studies 
evaluating neuroimaging, neuropsychological, nega-
tive life events and genetic parameters with larger sam-
ple sizes remain needed to better understand the link 
between cannabis use and schizophrenia.
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